COMMUNIQUÉS West-GlobeNewswire

Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
24/02/2026
Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting February 24, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox [...]
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
23/02/2026
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with [...]
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
23/02/2026
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025 Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: [...]
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
23/02/2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct [...]
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
24/02/2026
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company [...]
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
23/02/2026
Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million , an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating [...]
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
23/02/2026
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a [...]
PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day
23/02/2026
SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]
Supernus Pharmaceuticals to Participate in March Investor Conferences
24/02/2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Sana Biotechnology to Present at March 2026 Investor Conferences
23/02/2026
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its [...]
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
23/02/2026
Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business [...]
Silo Pharma Announces Share Buyback Program
23/02/2026
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, [...]
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
23/02/2026
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform [...]
Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
23/02/2026
CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity [...]
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
23/02/2026
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, [...]
Ultragenyx to Participate at Investor Conferences in March
23/02/2026
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]

Pages